Methods of using zonisamide as an adjunctive therapy for partial seizures
are disclosed. In particular, the methods enhance the safety of patients
taking pharmaceutical formulations of zonisamide by providing information
that increases the awareness of hyperammonemia as a possible side effect;
wherein the patients and/or prescribing physicians and other medical care
providers are advised to monitor for hyperammonemia and employ methods
that will improve the therapeutic outcome in the few patients who
experience hyperammonemia associated with zonisamide therapy.
